Search

Avita steady after FDA approves trial

Shares in Avita Medical were unchanged today despite receiving approval from the US Food and Drug Administration (FDA) to begin clinical trials of its ReCell Spray-On Skin device early next year, after the company suspended initial trials in 2008.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/10/18

1 year TSR5 year TSR
55thAvita Medical90%-1%
97thI Synergy Group52%0%
232ndMustera Property Group16%0%
293rdKatana Capital5%4%
630thAdmedus-43%-38%
744 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

29/12/17
$75k Bought
29/12/17
$10k Bought
28/12/17
$5k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

84th↓Admedus$11.7m
85th↑Mustera Property Group$11.4m
86th↑Avita Medical$11.3m
87th↑I Synergy Group$10.8m
88th↑Katana Capital$10.3m
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer